GB2224652A - Gelled haemostatic agents - Google Patents

Gelled haemostatic agents Download PDF

Info

Publication number
GB2224652A
GB2224652A GB8923711A GB8923711A GB2224652A GB 2224652 A GB2224652 A GB 2224652A GB 8923711 A GB8923711 A GB 8923711A GB 8923711 A GB8923711 A GB 8923711A GB 2224652 A GB2224652 A GB 2224652A
Authority
GB
United Kingdom
Prior art keywords
gel
silicon dioxide
solution
colloidal silicon
gel according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8923711A
Other versions
GB2224652B (en
GB8923711D0 (en
Inventor
Martin Whitefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DERMAL LAB Ltd
Original Assignee
DERMAL LAB Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DERMAL LAB Ltd filed Critical DERMAL LAB Ltd
Publication of GB8923711D0 publication Critical patent/GB8923711D0/en
Publication of GB2224652A publication Critical patent/GB2224652A/en
Application granted granted Critical
Publication of GB2224652B publication Critical patent/GB2224652B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/008Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Colloid Chemistry (AREA)
  • Silicon Compounds (AREA)

Description

2224652 - 1 HAEMOSTATIC AGENTS This invention relates to haemostatic
agents and their preparation and use.
An aqueous solution containing about 20 to 22% w/v calculated as iron (III) of ferric subsulphate (or basic ferric sulphate of suggested formula Fe4 O(SO 4)5 or Fe 4 (OH) 2 (SO 4)5) is widely used as a haemostatic agent under the name of Monsel's solution. The concentration is calculated in terms of iron (III) owina- to the uncertal.7.1 -ion about the precise formula of the Monsel salt. The solut is applied by topical application to superficial wounds anJ abrasions and has proved particularly useful after punch -tage. biopsies and removal of localised skin lesions b,,cure'. It has also been proposed as a haemostatic agent for use after cervical biopsy, shave excision, nail fold biopsy, nail matricectomy, and cerumen removal.
While Monsel's solution is an effective haemostatic agent, it is not entirely satisfactory in use. More particularly, it is a very acid solution and, because of its iron content, is liable to cause staininQ which creates serious problems if it is spilled. It must therefore be handled and applied with care. Additionally, because of its high concentration which approaches satiration, the solute is liable to crystallise out even on short term storage and especially if the solution is stored at low temperatures or allowed to evaporate.
Solutions of aluminium chloride hexahydrate in water or aqueous alcohol (ethanol or isopropyl alcohol) containing 20 to 70% w/v of the salt (calculated as the hydrated salt) are also used as haemostatic agents.
We have now discovered that these known haemostatic solutions may be made very much easier and more convenient to handle without in any way impairing their valuable haemostatic properties, by formulating them as gels containing colloidal silicon dioxide.
The present invention accordingly provides a haemostatic composition in the form of an aqueous or a,oeous alcoholic solition of basic ferric sulphate or alu-.-J.-ium chloride hexahydrate, and sufficient colloidal silicon dioxide to gel the mixture. The solution is gelled when it cannot be poured but can still be expelled from a narrow nozzle and applied in small quantity to the site to be treated. The gel is thixotropic and its viscosity is reduced markedly when it is subjected to shear. This makes measurement of the viscosity unreliable, but it is in practice satisfactory to rely on visual inspection to obtain a gel which is sufficiently mobile for transfer and packinj in nozzled, unit dose containers. Unexpectedly, in the presence of the silicon dioxide, the gel shows a gre-nt-', reduced tendency to crystallise even on prolonged standing at reduced temperatures and shows a reduced tendency to dry out.
Colloidal silicon dioxide is submicroscopic fumed silica prepared by the vapour phase hydrolysis of a silicon compound. It is commercially available in a variety of particle sizes (and surface areas). For use in the present invention colloidal silicon dioxide preferably has a surface area in the range of 150 to 250 m2 /9 by BET measurement and especially about 200 m 2, /9. Only a small proportion, usually in the range of 3 to 6%, preferably 4 to 5%, by weight of the colloidal silicon dioxide is required to produce a gel when incorporated into Monsel's solution. A slightly higher amount, 4 to 10% by weight, is required to gel alu,,r.iniuT. chloride solution.
Surprisingly it has been discovered that the Monsells solution must have a sufficient content of sulphate for the required gel to be produced with a small quantity (below 6%) of colloidal silicon dioxide. Some samples of Monsel's solution contain insufficient sulphate to produce a gel with this quantity of colloidal silicon dioxide, and in that case it is necessary to add a small amount (up to 10% weight for weight) of concentrated sulphuric acid to gel the mixture. The specific gravity of Monsells solution provides a convenient indication of its sulphate content. A density - 4 of >1.6 normally indicates that no additional sulphuric acid is required.
Under normal circumstances, silicon dioxide gels aqueous solutions only between pH limits of 5 and 9. Since the pH of Monsel's solution is below 0.5, it is very surprising that the gelling effect actually occurs. This may be due to a contribution from, the sulphate ion as, if there is insufficient sulphate present in the basic salt to 1 produce a gel, further sulphuric acid must be added as note. above. Addition of other acids, such as hydrochloric acid, is far less effective.
Monsel's solution may be prepared in known manner. For use in the present invention it should have a pH below 0.5 and for rapid haemostatic activity, a concentration of iron (III) in the range 15 to 20% w/v, corresponding approximately to a Monsel's salt content in the aqueois solution of 48 to 64% w/v, not including the added colloidal silicon dioxide. Lower concentrations may be used where a slower effect is acceptable, i.e. 6 to 15% w/v iron (III), corresponding approximately to 20 to 48% w/v of Monsel's salt, although this would require a higher concentration of silicon dioxide, (e.g. up to 10%), to produce a suitable gel. ConcentraIC ions of iron (III) above 20% w,.,v up to saturation can also be used but such solutions are liable to deposit crystals on lonc standing even in the presence of the colloidal silicon dioxide, and such concentrations are therefore not preferred when the ability to withstand long storage, e.g. up to 2 years, without crystallization is required.
Aluminium chloride hexahydrate solutions in concentrations between 20 and 70% in aqueous alcoholic (ethanol or isopropyl alcohol) medium may be gelled using the same grade of colloidal silica (4 - 10% by weight) with the addition if necessary of hydrochloric acid (0.5 - 5% weight for weight).
The gelling agents normally used in compositions for topical application are unsuitable for use with these solutions because of the high degree of acidity of the latter which decomposes gelling agents such as cellulose derivatives or gums, or is incompatible with gel formation by other agents (e.g. Carbopol). Further the high concentration of iron (III) in Monsel's solution is incompatible with gel formation with materials such as agar or silicate salts which would react with the basic ferric sulphate. Surprisingly it has been found that colloidal silicon dioxide can be used to produce a semi-solid gel from either Monsells solution or aluminium chloride solution which is clear, or at Least translucent. The gei is ea-.... t-apply topically and shows a greatly reduced tendency to spread from the desired application area or to crystallise out on storage, as compared with the ungelled solutions while the presence of the silicon dioxide in no way interferes with the haemostatic activity. Surprisingly, it actually appears to enhance the effect and to encourage faster blood coagulation.
The gelled solution is conveniently dispensed in small plastic containers each containing a unit dosage of the gel, i.e. enough for one haemostatic application.' The individual plastic containers must, of course, be resistant to the gel and are preferably squeezable to extrude the gel. Small sachets of, for example, polyethylene or other inert plastics material are suitable. Dispensing the gel from such containers is a very much simpler more rapid and more certain procedure than applying ungelled Monsells solution or ungelled aluminium chloride solution. Moreover, the risk of spillage, which can be very inconvenient with such highly acid materials is avoided.
The following Examples illustrate the invention.
EXAMPLE 1
1. Preparation of Monsel's solution Sulphuric acid (55m1) is added to distilled water (800m1) in a suitable vessel and the mixture is heated to - 7 about 100 C. Nitric acid (75m1) is then added. Hydrated ferrous sulphate (10459) in coarse powder form is then added in four approximately equal portions one after the other with stirring after each addition until the effervescence ceases. If, after all the ferrous sulphate has been added the solution is black, nitric is added a few drops at a time with heating and stirring until the black colour has disappeared and red fumes are no longer evolved. The solution is then boiled until it assumes a red colour and free nitrate can no longer be detected in it. The volume of the mixture is made up to about 1000m1 by addition of distilled water as needed. Finally the solution is cooled, adjusted in volume if necessary to 1000m1, and, if necessary, filtered to remove any suspended solid. The resulting solution is assayed for iron (III) and the weighlper ml is determined. The solution is then diluted, if necessary, using water and/or sulphuric acid to obtain the required strength and sulphate content necessary for formulating into the gel. A solution containing for example 15 to 20g of iron (III) per 100m1 may be used for the next step.
2. Preparation of the gel Colloidal silicon dioxide havin a surface area by BET measurement of 200 + 30m2/g (Wacker-Chemie Hydrophilic HDK grade N 20) is added to the Monsel's solution prepared as described above at a concentration of 4.5% by weight and thoroughly mixed in to produce a homogeneous dispersion. The mixture is left for 2 to 3 hours for the particles of silica to become fully hydrated and then mixed further to disperse any gel agglomerates and provide a smooth homogeneous preparation. At this stage, if the viscosity is too low and the solution has not gelled, concentrated sulphuric acid is added in small portions with qontinuous mixing until the required viscosity is obtained. This is indicated by the formation of a semi-solid aqueous gel which may be packed conveniently into a unit dose, polyethylene, tube-like container and dispensed by squeezing through a narrow orifice (1-3mm diameter) onto or into the affected skin site. Measuring the actual viscosity is only of theoretical interest as this type of gel is highly thixotropic which is an advantage in clinical usage. Although under shear the gel loses viscosity and may therefore easily be extruded from its container and applied to the site, once deposited on or in the tissues it rapidly regains it original viscosity and recovers its relative immobility. This avoids the problems caused by spreading which occur with Monsells solution.
EXAMPLE 2
Preparation of aluminium chloride solution Aluminium chloride hexahydrate (500g) is dissolved in distilled water, with warming and then cooling if necessary, to produce a final volume of 1000m1.
2. Preparation of the gel The aluminium chloride gel is prepared in exactly the same manner as described in Example 1 for Monsel's solution with the exception that the gelling agent is added at a concentration of 6.5% by weight of the solution and concentrated hydrochloric acid is added, as necessarY, to produce the required viscosity.
-

Claims (9)

1. A gel for topical application comprising water or aqueous alcohol, basic ferric sulphate or hydrated aluminium chloride at concentration sufficient for haemostatic activity and sufficient colloidal silicon dioxide to gel the mixture.
2. A gel according to claim 1 comprising 15 to 20% w/v of basic ferric sulphate, calculated as iron (III).
3. A gel according to claim 1 or 2 comprising basic ferric sulphate and in which the proportion of the colloidal silicon dioxide is 3 to 6% by weight.
4. A gel according to claim 3 in which the proportion of colloidal silicon dioxide is 4 to 5% by weight.
5. A gel according to any one of claims 1 te 4 comprising 20 to 70% w/v of hydrated aluminium chloride (calculated as the hydrated salt) and in which the proportion of the colloidal silicon dioxide is 4 to 10% by wei ght.
6. A gel according to any one of claims 1 to 5 in which the colloidal silicon dioxide has a surface area by BET measurement of 150 to 250m2 /g.
7. A gel according to any one of the preceeding claims having a pH of about 0.5 or less.
i 7 - 11
8. A gel according to claim 1 substantially as described in Example 1 or 2.
9. A plastic sachet containing a unit dose of a gel as claimed in any one of the preceeding claims.
Put.ishe-- 199C a' The Pat--- 2,fl:jce-St, H --E:, 6C - I-E-o-- H - SaAs Branc St Cr,- Crpng-,n Yent E t,r- zR:: P:,.ne-- es --.- S. m-. Ke:i. --
GB8923711A 1988-10-24 1989-10-20 Haemostatic gels comprising silicon dioxide and basic ferric sulphate or hydrated aluminium chloride Expired - Fee Related GB2224652B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888824850A GB8824850D0 (en) 1988-10-24 1988-10-24 Haemostatic agents

Publications (3)

Publication Number Publication Date
GB8923711D0 GB8923711D0 (en) 1989-12-06
GB2224652A true GB2224652A (en) 1990-05-16
GB2224652B GB2224652B (en) 1992-05-06

Family

ID=10645688

Family Applications (2)

Application Number Title Priority Date Filing Date
GB888824850A Pending GB8824850D0 (en) 1988-10-24 1988-10-24 Haemostatic agents
GB8923711A Expired - Fee Related GB2224652B (en) 1988-10-24 1989-10-20 Haemostatic gels comprising silicon dioxide and basic ferric sulphate or hydrated aluminium chloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB888824850A Pending GB8824850D0 (en) 1988-10-24 1988-10-24 Haemostatic agents

Country Status (2)

Country Link
US (1) US5011693A (en)
GB (2) GB8824850D0 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635162A (en) * 1995-02-23 1997-06-03 Ultradent Products, Inc. Hemostatic composition for treating gingival area

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5575995A (en) * 1991-08-15 1996-11-19 Giovanoni; Richard L. Ferric subsulfate gel and methods of using same
US5827884A (en) * 1995-09-15 1998-10-27 Omp Acquisition Corporation Skin peel maintenance composition and method
US6652840B1 (en) * 2001-02-21 2003-11-25 Terence Prevendar Bleeding control and healing aid compositions and methods of use
US20090041858A1 (en) * 2007-08-06 2009-02-12 Cao Group, Inc. Haemostatic Compositions Thickened by Polymers Containing Nitrogen Moieties
CN101653454B (en) * 2008-08-22 2011-07-06 谭国梁 Medicament capable of dehydrating and withering pathological tissues
US8840931B2 (en) 2008-08-22 2014-09-23 Kuok Leong Tam Pharmaceutical compositions for dehydrating, atrophying and eliminating pathological tissues
US20110077512A1 (en) * 2009-06-16 2011-03-31 Dept. Of Veterans Affairs Biopsy marker composition and method of use
HRP20180979T1 (en) * 2012-09-19 2018-09-21 Eupharma Pty Ltd Viscous haemostatic compostions and method of treatment
EP4378490B1 (en) 2022-12-01 2026-02-04 Ascil Proyectos SL Haemostatic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856941A (en) * 1972-05-23 1974-12-24 Sobel J Astringent gel, its preparation and use
US4073887A (en) * 1973-02-09 1978-02-14 Edward Price McLean, Sr. Composition for treating ingrown toenails
US4224339A (en) * 1978-10-10 1980-09-23 Scott Eugene J Van Treatment of disturbed keratinization
US4551100A (en) * 1982-06-07 1985-11-05 Ultradent, Inc. Method of preparing gingival area for dental crowns
EP0200508B1 (en) * 1985-04-27 1991-10-02 Nitto Denko Corporation Adhesive oral bandages and oral pharmaceutical preparations
US4777041A (en) * 1986-08-07 1988-10-11 Charles Of The Ritz Group Ltd. Wrinkle treatment formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635162A (en) * 1995-02-23 1997-06-03 Ultradent Products, Inc. Hemostatic composition for treating gingival area
US5785955A (en) * 1995-02-23 1998-07-28 Fischer; Dan E. Hemostatic compositions for treating soft tissue

Also Published As

Publication number Publication date
GB2224652B (en) 1992-05-06
US5011693A (en) 1991-04-30
GB8923711D0 (en) 1989-12-06
GB8824850D0 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
US4450151A (en) Powder aerosol composition
US5011693A (en) Haemostatic agents
JPH057062B2 (en)
BRPI1001318A2 (en) freeze-dried molded article containing magnesium ascorbyl phosphate
KR870001372B1 (en) Skirt composition and its manufacturing method
US3164523A (en) Composition for skin beautification and treatment
JPS6021567B2 (en) Patch cosmetics
US3592936A (en) Method of treatment using pharmaceutical composition containing dimethyl sulfoxide
EP0402933B1 (en) Use of sucralfate humid gel as vehicle for drugs having topic activity and for cosmetics
US5575995A (en) Ferric subsulfate gel and methods of using same
AU633815B2 (en) Antiperspirant and method of making same
JP3130262B2 (en) Bath additive
US5275806A (en) Topical compositions for protection against ultraviolet radiation
US6726933B2 (en) Rod-shaped mesoporous powder, humectant adsorbing powder, and cosmetic preparation using the same
JPS60115506A (en) Pack
JPH07505869A (en) moisturizer
JPH10506085A (en) Moldable alum composition
EP0407003B1 (en) Gelling composition
JPS58183701A (en) Improved gum arabic
JPH06179614A (en) Pack cosmetic
JPH03109312A (en) Capsule for cosmetic application and method of its production
JPS6226214A (en) Solid bath composition slowly soluble in hot water
JPS6117506A (en) Clay-like pack cosmetic
JPS58109408A (en) Oral composition
JPS624216A (en) Pack cosmetic

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19981020